key: cord-0880349-bmg8uok8
authors: Bankova, Andriyana K.; Caveney, Joseph; Yao, Bin; Ramos, Teresa L.; Bögeholz, Jan; Heydari, Kartoosh; Diaz, Nery; Jackson, Marin L.; Lowsky, Robert; Brown, Janice (Wes); Johnston, Laura; Rezvani, Andrew R.; Frank, Matthew J.; Muffly, Lori; Weng, Wen-Kai; Sidana, Surbhi; Negrin, Robert S.; Miklos, David B.; Shiraz, Parveen; Meyer, Everett H.; Shizuru, Judith A.; Arai, Sally
title: Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report
date: 2022-01-15
journal: Transplant Cell Ther
DOI: 10.1016/j.jtct.2022.01.010
sha: ff9a917230278e41d41bca97036012f19344caef
doc_id: 880349
cord_uid: bmg8uok8

BACKGROUND: As a result of the COVID-19 widespread pandemic, cryopreservation of allogeneic donor apheresis products was implemented to mitigate the challenges of donor availability and product transport. Although logistically beneficial, the impact of cryopreservation on clinical outcomes and graft composition remains unclear. OBJECTIVES: To compare the outcomes and graft composition with cryopreserved versus fresh allografts in the setting of allogeneic hematopoietic cell transplantation (allo-HCT). STUDY DESIGN: We retrospectively analyzed the clinical outcomes of 30 consecutive patients who received cryopreserved allografts between March and August 2020 as compared to 60 consecutive patients who received fresh allografts prior to the COVID-19 pandemic. Primary endpoints were hematopoietic engraftment, graft failure (GF) and secondary outcomes were overall survival (OS), relapse free survival (RFS) and non-relapse mortality (NRM). In addition, extended immunophenotype analysis was performed on cryopreserved versus prospectively collected fresh apheresis samples. RESULTS: Compared to fresh allografts, both neutrophil and platelet recovery were delayed in recipients of cryopreserved reduced intensity conditioning (RIC) allo-HCT with median times to engraftment of 24 days vs 18 days (P = .01) and 27 days vs 18 days (P = .069), respectively. We observed primary GF in 4 of 30 patients in the cryopreserved cohort (13.3%) vs only one of 60 patients (1.7 %) in the fresh cohort (P = .03). Cryopreserved RIC allo-HCT was associated with significantly lower median total, myeloid and T-cell donor chimerism at 1 month. OS and RFS were inferior for cryograft recipients with hazard ratio [HR (95%Cl)]: 2.16 (1.00, 4.67) and 1.90 (0.95, 3.79), respectively. Using an extended immunophenotype analysis we compared 14 samples from the cryopreserved cohort to 6 prospectively collected fresh apheresis donor samples. These analyses showed both decrease in total cell viability and significantly reduced absolute numbers of NK cells (CD3(−)CD56(+)) in the cryopreserved apheresis samples. CONCLUSION: In this single institution study we note delayed engraftment and a trend toward clinical inferiority of cryopreserved vs fresh allografts. Further evaluation of the use of cryopreserved allografts and their impact on clinical and laboratory outcomes is warranted.

*These authors contributed equally to this work. In 2020, because of the COVID-19 pandemic, widespread cryopreservation of allogeneic donor apheresis products was implemented to mitigate the challenges of donor availability and product transport. During the early phase of the pandemic from March until August 2020 in the USA, the National Marrow Donor Program (NMDP) required the cryopreservation of all unrelated donor (URD) grafts. Prior to the pandemic, data available from single center or small multi-center reports showed conflicting results regarding post-HCT clinical outcomes of cryopreserved allografts. [2] [3] [4] One of these studies comparing cryopreserved with fresh peripheral blood stem cell (PBSC) grafts from related donors showed similar clinical outcomes in regards to overall survival (OS), non-relapse mortality (NRM), acute and chronic graft-versus-host disease (GVHD), and hematopoietic recovery. 2 In contrast, two other studies showed increased rates of graft failure (GF) with cryopreserved URD PBSC grafts 3 and delayed platelet recovery with cryopreserved related and URD PBSC grafts. 4 Since the institution of pandemic restrictions, the Center for International Blood and Marrow Transplant Research (CIBMTR) has reported on three retrospective studies the clinical outcomes of cryopreserved as compared to fresh allogeneic donor products. [5] [6] [7] The study by Eapen and colleagues 5 , which focused on patients with severe aplastic anemia, showed higher rates of GF and inferior OS with cryopreserved allografts. Whereas the study by Hamadani and colleagues which included only patients undergoing allo-HCT with post-transplantation cyclophosphamide (ptCy) as GVHD prophylaxis 6 , showed similar outcomes for cryopreserved as compared to fresh allografts. The more recent and largest study by Hsu and Cancer Centre, who underwent allo-HCT between 2010 and 2018. No differences were observed in hematopoietic recovery, GF, incidence of acute and chronic GVHD and OS in recipients of cryopreserved as compared to fresh grafts. 8 The different outcomes reported in the latter study could be mainly attributed to the differences in the graft sources used in the analysis, since the majority of patients (91%) who received cryopreserved grafts had matched related donors (MRD) and only 9% received URD grafts, as compared to the fresh cohort in which 83% were from URD. Importantly, this imbalance in the graft source differs substantially from the real-time experience during the COVID-19 pandemic, since nearly all URD grafts were cryopreserved. One recent publication from the Dana-Farber Cancer Institute comparing cryopreserved to fresh URD PBSC grafts in the context of the COVID-19 pandemic reported lower T-cell chimerism, impaired immune reconstitution the first months post allo-HCT, as well as increased GF linked to longer transit time (>48 hrs) independent of cryopreservation. No differences in 6-month OS, PFS or NRM were noted. 9 In our center, we observed a highly unusual cluster of GF in patients undergoing reduced intensity conditioning (RIC) allo-HCT which correlated with the institution of URD cryopreservation beginning in March 2020. Therefore, we compared clinical outcomes of 30 consecutive patients who underwent allo-HCT with cryopreserved PBSC grafts during the COVID-19 pandemic with 60 consecutive patients, who received fresh PBSC grafts prior to the pandemic cryopreservation requirement. In prior studies the variable of conditioning intensity, has not been reported. Hence, we separately assessed the effect of graft cryopreservation on the outcomes of patients undergoing RIC versus myeloablative conditioning (MAC). Furthermore, to study if differences in cell composition might be present between cryopreserved and fresh grafts, we carried out extended phenotype analyses of hematopoietic stem cell (HSC) and lymphocyte subsets on available samples from the cryopreserved PBSC products, and prospectively collected and analyzed fresh allogeneic PBSC samples. To our knowledge our study is the first to include extended phenotyping of the graft composition, which we believe will further elucidate the biological relevance of the different cellular subpopulations in regard to clinical outcomes.

Data were retrospectively collected from 30 consecutive patients who underwent allo-HCT with cryopreserved PBSC (cryopreserved cohort) from March until August 2020 and compared to a control cohort of 60 consecutive patients, who received fresh PBSC allo-HCT (fresh cohort) from June 2019 to March 2020. All patients included in the analysis underwent either MAC or RIC. Patients receiving a total lymphoid irradiation (TLI), anti-thymocyte globulin (ATG) and low dose total body irradiation (TBI) RIC were excluded from this analysis given that (1) this TLI/ATG/TBI reduced-intensity regimen is center specific and (2) this regimen leads to higher rates of mixed donor chimerism compared to other RIC regimens. 10 Donors included HLA-matched siblings, HLA-matched unrelated, haploidentical relatives and HLA-mismatched unrelated. All patients had provided written informed consent and the study was approved by the Institutional Review Board (IRB) of Stanford University.

Primary endpoints were time to hematopoietic engraftment of neutrophils and platelets and GF. Neutrophil recovery was defined as the date of the first of three consecutive days with an bs ute eutr phi c u t (ANC) ≥ 0.5 x 10 9 /L and platelet recovery was defined as the date f the first p te et c u t ≥20 x 10 9 /L without transfusion for the last 7 days. Primary GF was defined as initial donor chimerism < 5% or f i ure t chieve ANC ≥ 0.5 x 10 9 /L without morphological evidence of disease relapse. Secondary GF was defined as decrease in donor chimerism to < 5% fter i iti successfu e gr ftme t r decre se i ANC ≤ 0.5 x 10 9 /L without morphological evidence of disease relapse. Poor graft function was defined as two or three cytopenic lines (Hb <10 g/dL, ANC <1.0 × 10 9 /L, platelet count <30 × 10 9 /L) for >2 consecutive weeks beyond day +28, without transfusion support and in the presence of complete donor chimerism. 11 Secondary endpoints were chimerism levels post allo-HCT, OS, Relapse Free Survival (RFS) and NRM. Donor cell chimerism of whole blood and lineage subsets were assessed by short tandem repeat (STR) analysis as previously described. 12 To assess T-cell and myeloid chimerism, immunomagnetic beads coated with monoclonal antibodies against CD3 and CD15 were used to separate these fractions in peripheral blood. 10 For OS, death from any cause was considered an event, and surviving patients were censored at last contact. For RFS, relapse or death, whichever occurred earlier, was considered an event, and surviving patients without relapse were censored.

Disease state was reported as myeloid, lymphoid or mixed. Disease Risk Index (DRI) was calculated for each patient according to disease and stage risk by using standard criteria. 

In the cryopreserved cohort 28 apheresis products were cryopreserved at our center, whereas only 2 apheresis products underwent cryopreservation at the donor center. Cryopreservation at our center was performed according to standard operating procedure, using 10% dimethylsulfoxide (DMSO)/normosol media, followed by cryopreservation in an automated controlled-rate freezer. On the day of infusion cryopreserved products were transported to the patient unit in liquid nitrogen transporter, thawed, using 37 warm bath and infused.

Analysis of cryopreserved grafts was performed on available quality control (QC) samples collected on patients in the cryopreserved cohort. Briefly, QC vials were obtained from the actual products after adding 10% DMSO/normosol media and were frozen in the same controlled-rate freezer as the apheresis products. On the day of analysis, QC vials were thawed in warm bath for 1-2 min, resuspended in warm RPMI media (containing 10% FBS) and DNAse to avoid clumping, and centrifuged for 10 min at 500xg at room temperature (RT). Cells were counted on a Countess automated cell counter (Invitrogen) and mononuclear cells (MNC) were isolated using Ficoll density gradient separation (in cases with low cell count at baseline no Ficoll step was performed). Fresh apheresis samples were prospectively obtained from related donors at the day of collection and processed immediately. After cell counting, mononuclear cells (MNC) were isolated using Ficoll density gradient separation as described above. All P-values were two-sided and statistical significance was assessed at the nominal level of .05 without multiplicity adjustment. 

Neutrophil recovery was significantly delayed in the RIC cryopreserved cohort with median time to neutrophil engraftment of 24 days as compared to 18 days for the RIC fresh cohort (P = .01; Figure 1A ). Platelet engraftment was also delayed in the RIC cryopreserved cohort with median time to engraftment 27 days as compared to 18 days in the RIC fresh cohort (P = .069; Figure 1B ). The median time of neutrophil engraftment in MAC allo-HCT recipients was 19 days in the cryopreserved vs 14 days in the fresh cohort (P = .53); and the median time to platelet engraftment was 24 days in the cryopreserved versus 17 days in the fresh cohort (P = .73; Figure 1C and 1D). In a subgroup analysis, examining only URDs, we observed similar results with significant delay in both neutrophil and platelet recovery (Supplemental Figure 1 ).

Primary GF was documented in 5 patients amongst all 90 patients analyzed: 4 of 30 patients were in the cryopreserved cohort (13.3%) and one of 60 patients (1.7 %) in the fresh cohort (P = .03). In a subgroup analysis, including only URDs, we observed similar results with significant higher rate of GF (P = .03).

Extended information about disease and transplant characteristics for the 5 GF patients are presented in Table 2 

The median follow-up time in the fresh cohort was 15.4 months as compared to 9.9 months in the cryopreserved cohort. In a univariate analysis, OS for cryograft recipients was inferior as compared to fresh graft recipients [HR (95%Cl): 2.16 (1.00, 4.67); P = .050, Figure 3A ). In both cryograft recipients that received either RIC or MAC there was a trend of inferior OS (Supplemental Figure 4A Figure 5A and B]. However, these differences were of borderline statistical significance (P = .071) for the entire patient cohort and did not reach statistical significance in the conditioning subgroups. The cumulative incidence of NRM was higher in the cryopreserved cohort ( Figure 4A ) and this trend was also observed in the conditioning subgroups ( Figure 4B and C).

We performed a multivariable Cox model for OS by graft type (cryopreserved vs fresh) while adjusting for donor age, patient gender, donor type, CD34+ cell dose, conditioning intensity and DRI. There was no statistically significant difference in OS by graft type [HR (95% CI):

1.48 (0.62, 3.52); P = 0.4; Table 3 ]. Similarly, in a multivariable logistic regression model for GF by graft type (cryopreserved vs fresh), adjusted for donor age, patient gender, CD34+ cell dose, conditioning intensity and DRI, no statistically significant increase in GF was observed in the cryopreserved cohort [OR (95% CI): 6.99 (0.80, 168); P = 0.12; Table 4 ].

We performed extended immunophenotype analysis by flow cytometry on 14 available donor apheresis samples from the cryopreserved cohort and compared these data to 6 prospectively collected fresh donor apheresis samples. The analyses included cell viability, hematopoietic stem and progenitor cell (HSPC) content and immune cell subsets. Cell viability as assessed by Propidium Iodide was significantly reduced in cryopreserved as compared to fresh grafts ( Figure 5A ; P < .0001). However, the absolute counts of CD34 + cells or more stringent HSC (CD34 + CD38 -CD90 + CD45RA -) were similar for both groups ( Figure 5B and C). The flow cytometry gating strategy used to identify the CD34 + cells and HSC is shown in Supplemental Figure 6 .

In contrast to the stable quantity of HSPC populations present in grafts under the conditions of cryopreservation and thaw, analysis of the lymphocyte subsets revealed a significant decrease in the absolute numbers of NK cells, phenotypically defined as CD3 -CD56 + cells ( Figure 5D and 5E) in the cryopreserved vs fresh donor apheresis samples. Absolute counts of total T-cells (CD3 + CD56 -) and B-cells (CD19 + CD20 + ) did not differ in the cryopreserved vs fresh samples ( Figure 5E ). However, there was a trend toward decreased absolute numbers of CD4 memory T-cells (CD45RO + ) in cryopreserved samples, but no differences in the absolute numbers of total and naïve (CD45RA + ) CD4 + T-cells ( Figure 5F ) were observed.

Total, naïve and memory CD8 T-cell counts were similar in the fresh and cryopreserved samples ( Figure 5G ). Also, no statistically significant differences were observed in regulatory T-cells (Tregs; CD3 + CD4 + CD25 + CD127 -) between the two groups (Supplemental Figure 7A and B).

Our single center retrospective analysis reports real-world experience with cryopreserved allogeneic PBSC grafts during the COVID-19 pandemic examining both clinical impact and graft characteristics. We observed in univariate analysis that cryopreserved allo-HCT was associated with delayed hematopoietic recovery, increased primary GF, decreased OS and trends toward decreased RFS, and increased NRM. These data are consistent with the recently reported results from the largest retrospective study of the CIBMTR database. 7 However, in a multivariable analysis cryopreservation was not associated with statistically significant inferior OS or increased rate of GF. Given the small study size and the observed trend toward inferiority for the cryopreserved cohort, future studies with larger numbers of patients are warranted.

By assessing the subgroups of RIC and MAC allo-HCT we noted that the differences in neutrophil and platelet engraftment between cryopreserved and fresh cohort were primarily associated with RIC allo-HCT. Also, all patients with GF in the cryopreserved cohort underwent RIC allo-HCT. At our institution standard-of-care RIC regimens are comprised of either Flu/Mel or Flu/TBI, and for these regimens we do not standardly use in vivo lymphodepletive serotherapy such as ATG and Alemtuzumab. Interestingly, we did not observe increase in GF in patients who underwent our institution-specific lower intensity conditioning with TLI/ATG/TBI, who received cryopreserved grafts (data not shown).

The negative experience with frozen allogeneic products contrasts the decades-long Similarly, a recent study by Maurer and colleagues which included allo-HCTs conducted before and during the COVID-19 pandemic showed that greater PBSC product age (>48 hrs), independent of cryopreservation, was associated with increased GF; and impaired immune reconstitution was observed in recipients of cryopreserved grafts. 9 Wiercinska and colleagues showed that median post-thaw recovery of viable CD34+ cells was 42% compared to viability > 90% prior to cryopreservation of HSC products. 15 Although in our center cell viability and CD34 + cell content is not routinely measured after thawing of cryopreserved grafts we were able to evaluate these parameters by flow cytometry in available samples from the cryopreserved grafts and compare them to prospectively freshly collected allogeneic graft samples. Importantly, we did not observe decrease in the absolute counts of CD34 + cells and HSC and only a slight decrease in viability, which was consistent among the cryopreserved samples.

Given that (1) pre-freeze CD34+ cells/kg were not notably different in the two groups and (2) post-thaw numbers of CD34+ cells and HSC were similar in the cryopreserved as compared to the fresh apheresis samples, our experience suggested that the cryopreservation and storage may have negatively impacted the amount or activity of non-CD34 gr ft "f ci it ti g ce s".

Replete allogeneic hematopoietic grafts are known to contain non-HSC cells that facilitate donor HSC engraftment. [16] [17] [18] [19] In the absence of sufficient myelo-and lymphoablation these 24, 27 Our data are consistent with previous reports that raise concerns about a universal practice of cryopreservation for allo-HCT. 5,7,9 A strength of our study is that patients in both the cryopreserved and fresh cohort were consecutively collected, thereby minimizing selection bias. Moreover, patients who underwent cryopreserved allo-HCT were transplanted between

March and August 2020 and represent our real-time experience during the COVID-19

pandemic. In addition, our results provide important observations regarding the consequences of cryopreserved allo-HCT in the context of conditioning intensity. Finally, we identified changes in the allograft composition elicited by the process of cryopreservation/thaw that have not been previously reported. We acknowledge that our study has limitations, including the imbalances between the two groups in regard to donor type at baseline and the relatively shorter observation period for the cryopreserved compared to the fresh cohort. Furthermore, because the analysis of immunophenotype of the cryopreserved products was not performed at the time of infusion, it is possible that length of storage time in liquid nitrogen might negatively impact the NK cell population.

In summary, our analysis revealed detrimental clinical outcomes associated with the cryopreservation of an allogeneic graft. Alterations in graft composition caused by prolonged product storage prior to freezing and the act of cryopreservation itself should be considered as contributing factors to this effect. Given the need to optimize strategies for HCT care during the COVID-19 pandemic, which continues to impose challenges in transportation and donor availability worldwide, further evaluation of the use of cryopreserved grafts and its impact on both clinical and laboratory outcomes is warranted. 

Fund for Cancer Research (to JAS), and the HL Snyder Medical Foundation (to JAS) AUTHORSHIP: Contribution

conducted the statistical analysis

wrote the manuscript

Has allogeneic stem cell cryopreservation been given the 'cold shoulder'? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation

Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts

Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM

Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival

Cryopreserved Grafts for Severe Aplastic Anemia

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis

The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis

Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors

Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic

Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site

Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans

Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment

Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells

CD8+TCR+ and CD8+TCR-cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers

The role of T cells in hematopoietic stem cell engraftment

Dog leukocyte antigen nonidentical unrelated canine marrow grafts: enhancement of engraftment by CD4 and CD8 T cells

Natural Killer Cells Improve

Hematopoietic Stem Cell Engraftment by Increasing Stem Cell Clonogenicity In Vitro and in a Humanized Mouse Model

Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation

CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation

Phenotypical and functional analysis of donor lymphocyte infusion products after long-term cryopreservation

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors

):cells (CD56 -CD3 + ), NK cells (CD56 + CD3 -), memory T cells

Absolute counts (cells/µl) of NK, T and B (CD19 + CD20 + ) cells as assessed by FACS in fresh as compared to cryopreserved apheresis samples. (F) Absolute counts (cells/µl) of total

+ T cells as assessed by FACS in fresh as compared to cryopreserved apheresis samples

Absolute counts (cells/µl) of total, memory and naïve CD8 + T cells as assessed by FACS in fresh as compared to cryopreserved apheresis samples

The authors thank Jessica Poyser for excellent laboratory management and technical support of the studies. This work was supported by the California Institute for Regenerative Medicine (grant DR2A-05365 to JAS), the National Institutes of Health (grant NCI P01CA049605 and NHLBI